Aspen Shares Nosedive 15% on JSE After Shock Profit Warning
Aspen Pharmacare shares see a sharp decline on the JSE following an alarming profit warning. What does it mean for investors?
Aspen Pharmacare shares see a sharp decline on the JSE following an alarming profit warning. What does it mean for investors?
Adcock Ingram reports steady annual profits as winter demand for Panado and Corenza-C drives growth in the second half.
The recent R15.5 billion ARV tender sidelines Pharma Giants in South Africa, raising questions about local production support.
Urgent public health reform is needed to protect vulnerable populations from being denied healthcare in South Africa's public facilities.
Discover the paradox of TB deaths in South Africa as new infections decline but mortality remains high. Learn more here.